Trial Profile
A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin/choline fenofibrate (Primary) ; Choline fenofibrate; Rosuvastatin
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Laboratories; AstraZeneca
- 31 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 29 Mar 2009 Primary endpoint 'High density lipoprotein cholesterol level' has been met.
- 29 Mar 2009 Primary endpoint 'Low density lipoprotein cholesterol level' has been met.